PD-L1 in tissue is being explored as a predictive biomarker for outcomes of PD-L1/PD-1 treatment in NSCLC, while there are some conflicting data from the predictive biomarkers of response in terms of the level of PD-L1 expression. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.